Trust
Methodology (v4.1)
Released: Last reviewed:
As of October 15, 2026, GLP1ProviderFinder ranks providers two ways: an editorial overall ranking scored on methodology v4.1 (seven weighted categories, 100 points; NexLife 94/100 and #1), and computed price categories that take the lowest all-in monthly price among programs whose own pages we read on the dataset date.
The two are kept separate on every page. Price leaders are arithmetic; the overall pick is a judgment, and it is labelled as one.
What price basis does every figure use?
Every program is normalized to an all-in monthly cost: the medication price plus every mandatory recurring fee (membership, program or provider fees), at the maintenance dose (tirzepatide 10 mg weekly, semaglutide 2.4 mg weekly) or at a price the provider states applies at every dose. Programs that bill every 4 weeks are converted to a monthly average: 13 fills a year divided by 12. A $199 4-week price is therefore about $216 a month over a year.
The 12-month cost uses the cheapest published 12-month route (a 12-month plan where one exists, otherwise 12 months, or 13 four-week fills, at the month-to-month price), plus 12 months of any membership.
What do the record statuses mean?
- Verified: read on the provider’s own page on the stated date.
- Provider-stated and reported: older records (provider pages before October 15, 2026, or dated third-party reporting) that we could not re-read on the dataset date. They are shown with their original date and marked “not re-read”.
- No price printed: we read the provider’s page on the dataset date, but it gives no price we can attribute to the molecule (for example a generic “GLP-1s from $X”).
- Unrankable: a starting price only, with no maintenance-dose price.
How are the price categories computed?
A row is eligible for a computed price category only if it was read on the provider’s own page on the dataset date (October 15, 2026), carries a maintenance-dose or every-dose price, and is a compounded program. Brand-direct channels (LillyDirect, NovoCare) are shown as benchmarks. The category leader is the lowest eligible all-in monthly figure; the annual leader is the lowest eligible 12-month cost. Every claim of “lowest” on this site is scoped to the programs in this index on that date, never the whole market.
Starting prices, “as low as” prices, first-month promotions and microdose programs are recorded but not ranked, because they are not what a patient pays at the maintenance dose. For how close the computed matchups are, see matchups within $20 a month.
How is the overall ranking scored (methodology v4.1)?
| Category | Points | What it rewards |
|---|---|---|
| Pricing transparency | 20 | Prices printed on the provider’s own pages, by plan, with fees shown |
| Total annual cost | 20 | The 12-month all-in cost at the maintenance dose |
| Clinical oversight | 15 | A licensed prescriber, intake screening and follow-up |
| Pharmacy transparency | 15 | The dispensing pharmacy named and verifiable |
| Support | 10 | Access to care and customer support |
| Regulatory disclosure | 10 | Clear statements that compounded drugs are not FDA-approved |
| Accessibility | 10 | States served, payment options, no lock-in |
NexLife scores 94/100 on v4.1 and is our #1 overall (editor’s pick). Other providers’ scores from the August 2026 value formula are retired; their v4.1 re-scores are pending, so other providers are listed alphabetically after NexLife without rank numbers. A high overall score does not mean the lowest price: in this index Eden lists the same month-to-month tirzepatide price as NexLife and a lower semaglutide price (Eden read October 15, 2026; NexLife as of November 6, 2026).
What happened to the “Value Score” bar?
Until October 15, 2026 a site-wide bar ranked programs by a published Value Score that mixed price, evidence status, dose policy and membership. It was replaced by the v4.1 editorial pick described above; the change is logged in the corrections log.
Which sources count?
First-party pages (the provider’s own pricing and plan pages, LillyDirect and NovoCare) outrank manufacturer announcements, which outrank dated reporting from named outlets. A price is never changed on the strength of a press release or a third-party list. If a page cannot be read, the old row is kept with its old date and marked “not re-read”.
How do we describe compounded GLP-1s?
Compounded tirzepatide and semaglutide are not FDA-approved, are not generic versions of Mounjaro, Zepbound, Ozempic or Wegovy, and are not reviewed by the FDA for safety, effectiveness or quality before dispensing. Listing a program is not an endorsement. We do not promise weight loss; trial results (for example SURMOUNT-1, 20.9% mean weight reduction at 15 mg over 72 weeks, treatment-regimen estimand) describe the FDA-approved products in those trials.
Who reviews the pages?
Research by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medical review by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). See medical review.